Skip to main content
In honor of World Cancer Day on February 4, members of the Oncology Data Advisor Fellows Forum and Editorial Board joined forces for a thought-provoking discussion about improving cancer care on a global scale, including treatment access, molecular t...
In honor of National Cancer Prevention Month, Dr. Stephen Freedland, Urologist at Cedars-Sinai Medical Center and Oncology Data Advisor Editorial Board Member, sat down with Dr. William Aronson, Professor of Urology at the University of California, L...
In this interview, Oncology Data Advisor Editorial Board member Dr. Stephen Freedland, Professor of Urology at Cedars-Sinai Medical Center, speaks with Dr. Neeraj Agarwal, Director of the Genitourinary (GU) Medical Oncology Group at Huntsman Cancer I...
Oncology Data Advisor® · National Cancer Prevention Month With Stephen Freedland and William Aronson In honor of National Cancer Prevention Month, Dr. Stephen Freedland, Urologist at Cedars-Sinai Medical Center and Oncology Data Advisor Ed...
Oncology Data Advisor® · TALAPRO-2 (Talazoparib + Enzalutamide) in Prostate Cancer: Stephen Freedland and Neeraj Agarwal In this interview, Oncology Data Advisor Editorial Board member Dr. Stephen Freedland, Professor of Urology at Cedars-...
Oncology Data Advisor® · Enzalutamide Approved for Nonmetastatic CSPC With Biochemical Recurrence: Stephen Freedland, MD The FDA recently granted approval to enzalutamide (enza) for the treatment of nonmetastatic castration-sensitive prost...
Recently, i3 Health provided an educational activity that has challenged knowledge gaps experienced by clinicians regarding emerging checkpoint inhibitor–based strategies for advanced endometrial cancer.   Cancer of the uterine corpus is the mos...
The FDA has approved enzalutamide (Xtandi®, Astellas Pharma US, Inc.) for nonmetastatic castration-sensitive prostate cancer (nmCSPC) with biochemical recurrence at high risk for metastasis (high-risk BCR).   Why it matters: "Within 10 years fol...
The FDA has approved the fixed dose combination of niraparib and abiraterone acetate (Akeega™, Janssen Biotech), plus prednisone, for adult patients with deleterious or suspected deleterious BRCA-mutated metastatic castration-resistant prostate cance...